Publications
- A comparative study of deferasirox and deferiprone in the treatment of iron overload in patients with myelodysplastic syndromes2013 | Publication without faculty affiliation
- Changes associated with lenalidomide treatment in the gene expression profiles of patients with Del(5q)2012 | First Faculty of Medicine
- Efficacy and safety of administration of oral iron chelator deferiprone in patients with early myelodysplastic syndrome2011 | First Faculty of Medicine
- Epigenetic silencing of the oncogenic miR-17-92 cluster during PU.1-directed macrophage differentiation2011 | First Faculty of Medicine
- Effect of erythropoietin on hepcidin expression in hemojuvelin-mutant mice2010 | First Faculty of Medicine
- Attenuated cell cycle and DNA damage response transcriptome signatures and overrepresented cell adhesion processes imply accelerated progression in patients with lower-risk myelodysplastic neoplasms2024 | First Faculty of Medicine, Faculty of Physical Education and Sport, Faculty of Science
- Expression of circular RNAs in myelodysplastic neoplasms and their association with mutations in the splicing factor gene SF3B12023 | Faculty of Science, Central Library of Charles University
- Luspatercept – a new contribution to the therapy of anaemia in patients with myelodysplastic syndrome2023 | First Faculty of Medicine
- Efficacy and safety of luspatercept versus epoetin alfa in erythropoiesis-stimulating agent-naive, transfusion-dependent, lower-risk myelodysplastic syndromes (COMMANDS): interim analysis of a phase 3, open-label, randomised controlled trial2023 | First Faculty of Medicine
- The benefit of luspatercept in the treatment of low‑risk myelodysplastic syndrome – case report2023 | First Faculty of Medicine
Loading network view...